Skip to content
Home/Companies/Biotech/ArsenalBio
ArsenalBio

ArsenalBio

Biotech·US·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns ArsenalBio?

ArsenalBio is currently owned by Hitachi Ventures through Hitachi Ventures Fund II (2021 vintage), since 2022.

Hand-verified · updated 2026-07-03

Hitachi Ventures
Investor
Hitachi Ventures
Hitachi Ventures Fund II · 2021 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive
Websitearsenalbio.com

More from Hitachi Ventures Fund II

Other portfolio companies in the same fund.

Ascend Elements
Active
EnergyUS· 2022
BeZero Carbon
BeZero Carbon
Active
ClimateTechUK· 2022
Makersite
Makersite
Active
SaaSGermany· 2022
Proscia
Proscia
Active
MedTechUS· 2022
Scipher Medicine
Scipher Medicine
Active
HealthTechUS· 2022
Weka
Weka
Active
SoftwareUS· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Antiverse
Antiverse
Active
Future Planet CapitalUK
Track ArsenalBio

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy ArsenalBio?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on ArsenalBio.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue